Hrd genes
Your sample will be analysed and a report will be generated, usually within three to four weeks of receipt of your sample in the laboratory. We will contact your pathologist directly and organise the collection of your sample and delivery to the laboratory. You will receive an email asking you to confirm that you have authorised ELG to be given a sample of your tumour tissue. Step 1: Purchase and permissionīuy the test. This test is only available with authorisation from your clinician, who will receive your test results directly.
You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 1270 699021. The hereditary aspect of the TumorNext-HRD test analysis can also indicate if other members of your family have significantly increased risk of certain cancers – so they too can arrange for appropriate monitoring or screening. This test can also indicate if you have a hereditary risk of developing other cancers – and therefore what steps you need to take for further screening or monitoring. The TumorNext-HRD test analyses 11 genes in your DNA to give you and your clinician clear indications of whether targeted PARP inhibitor treatment will help you. In effect, it causes tumour cells to die. It involves drugs which block an enzyme used by cancer cells to repair damage to their DNA caused by chemotherapy, but it doesn’t affect healthy cells. Most women who have ovarian cancer have particular gene mutations in their DNA – specifically those in BRCA1 and BRCA2 genes.īut that is not always the case, and if you have a different gene mutation, a new therapy that could help you is PARP inhibitor treatment.